GleamWall
中文EN

NRXS Neuraxis, INC

Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1933567 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY94.3%
TTM net income YoY-60.5%
TTM EPS YoY-9.1%
Revenue 3-yr CAGR37.0%
Net income 3-yr CAGR—

Margins

Gross margin86.2%
Operating margin-186.2%
Net margin-185.2%
FCF margin—
EBITDA margin-185.0%

Returns

ROE-409.7%
ROA-194.7%
ROIC (approx.)—
Asset turnover1.05x

Leverage & solvency

Liabilities / assets45.6%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-128.36x

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-90.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$3.57M$2.69M$2.46M$2.68M
Cost of revenue$562,916$362,002$303,345$297,060
Gross profit$3.01M$2.32M$2.16M$2.39M
R&D expense$493,611$433,614$169,315$225,610
SG&A expense$8.06M$7.58M$8.33M$5.12M
Operating income-$7.83M-$7.16M-$6.66M-$3.37M
Interest expense$73,969$174,328$476,416$318,666
Net income-$7.80M-$8.24M-$14.63M-$4.78M
EBITDA-$7.77M-$7.12M-$6.62M-$3.34M
EPS (basic)-0.95-1.22-4.50-2.77
EPS (diluted)-0.95-1.22-4.50-2.77
Weighted avg. shares (diluted)9.08M6.92M3.25M2.00M
Banking
Deposits$28,660$32,527$74,947$59,174
Balance sheet
Cash & equivalents$4.97M$3.70M$78,560$253,699
Receivables$195,703$244,618$73,167$174,399
Inventory$257,132$44,328$21,220$48,133
Current assets$5.73M$4.27M$242,610$476,957
PP&E, net$75,564$89,982$88,552$88,011
Intangibles$274,778$96,588$108,073$77,558
Total assets$6.40M$4.76M$509,498$1.48M
Current liabilities$2.79M$2.43M$1.89M$6.98M
Short-term debt$148,293$154,152$148,062—
Long-term debt———$228,342
Total debt———$228,342
Total liabilities$3.00M$2.69M$1.91M$7.05M
Shareholders' equity$3.40M$2.07M-$1.40M-$5.57M
Net debt———-$25,357
Shares outstanding10.65M6.99M6.51M1.96M
Cash flow statement
Operating cash flow-$6.43M-$6.10M-$6.69M-$2.30M
Capital expenditure$31,150$27,776$30,781$1,390
Free cash flow-$6.46M-$6.13M-$6.72M-$2.30M
Investing cash flow-$131,150-$27,776-$71,781-$61,205
Financing cash flow$7.83M$9.74M$6.59M$2.29M
Depreciation & amortization$59,501$37,831$40,725$37,133
Stock-based compensation$596,852$227,000—$27,319

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.